BR112021016435A2 - Receptores de antígenos quiméricos responsivos à hipóxia - Google Patents
Receptores de antígenos quiméricos responsivos à hipóxiaInfo
- Publication number
- BR112021016435A2 BR112021016435A2 BR112021016435A BR112021016435A BR112021016435A2 BR 112021016435 A2 BR112021016435 A2 BR 112021016435A2 BR 112021016435 A BR112021016435 A BR 112021016435A BR 112021016435 A BR112021016435 A BR 112021016435A BR 112021016435 A2 BR112021016435 A2 BR 112021016435A2
- Authority
- BR
- Brazil
- Prior art keywords
- hypoxia
- chimeric antigen
- nucleic acids
- antigen receptors
- responsive
- Prior art date
Links
- 206010021143 Hypoxia Diseases 0.000 title abstract 6
- 230000007954 hypoxia Effects 0.000 title abstract 5
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 4
- 102000039446 nucleic acids Human genes 0.000 abstract 4
- 108020004707 nucleic acids Proteins 0.000 abstract 4
- 150000007523 nucleic acids Chemical class 0.000 abstract 4
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000001146 hypoxic effect Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 230000001105 regulatory effect Effects 0.000 abstract 1
- 239000007787 solid Substances 0.000 abstract 1
- 229940124597 therapeutic agent Drugs 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70567—Nuclear receptors, e.g. retinoic acid receptor [RAR], RXR, nuclear orphan receptors
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4203—Receptors for growth factors
- A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/59—Reproductive system, e.g. uterus, ovaries, cervix or testes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2500/00—Specific components of cell culture medium
- C12N2500/02—Atmosphere, e.g. low oxygen conditions
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2304—Interleukin-4 (IL-4)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/30—Coculture with; Conditioned medium produced by tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Zoology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biomedical Technology (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Pharmacology & Pharmacy (AREA)
- Physics & Mathematics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Urology & Nephrology (AREA)
- Analytical Chemistry (AREA)
- Plant Pathology (AREA)
- Food Science & Technology (AREA)
- High Energy & Nuclear Physics (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1902277.1A GB201902277D0 (en) | 2019-02-19 | 2019-02-19 | Therapeutic agents |
| PCT/GB2020/050401 WO2020169974A1 (en) | 2019-02-19 | 2020-02-19 | Hypoxia-responsive chimeric antigen receptors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021016435A2 true BR112021016435A2 (pt) | 2022-01-18 |
Family
ID=65998727
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021016435A BR112021016435A2 (pt) | 2019-02-19 | 2020-02-19 | Receptores de antígenos quiméricos responsivos à hipóxia |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220195009A1 (https=) |
| EP (1) | EP3927734A1 (https=) |
| JP (1) | JP7684692B2 (https=) |
| KR (1) | KR20210132105A (https=) |
| CN (1) | CN113710695A (https=) |
| AU (1) | AU2020224373B2 (https=) |
| BR (1) | BR112021016435A2 (https=) |
| CA (1) | CA3130688A1 (https=) |
| GB (1) | GB201902277D0 (https=) |
| IL (1) | IL285587A (https=) |
| WO (1) | WO2020169974A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3922721A4 (en) * | 2019-03-12 | 2023-01-11 | Chongqing Precision Biotech Company Limited | PROMOTER REGULATED BY HYPOXIA AND ITS APPLICATION |
| JP2024530215A (ja) * | 2021-08-13 | 2024-08-16 | 上海▲シン▼湾生物科技有限公司 | 低酸素トリガーの人工転写因子、転写制御システム及びその応用 |
| US20250319126A1 (en) * | 2021-10-29 | 2025-10-16 | Shanghai Sinobay Biotechnology Co., Ltd. | Condition-controlled spliceable chimeric antigen receptor molecule and application thereof |
| CN114149510B (zh) * | 2021-10-29 | 2024-01-30 | 上海鑫湾生物科技有限公司 | 一种条件控制的可剪接嵌合抗原受体分子及其应用 |
| US20230227779A1 (en) * | 2022-01-19 | 2023-07-20 | Innovative Cellular Therapeutics Holdings, Ltd. | Enhanced Chimeric Antigen Receptor Cells in Hypoxic Tumor Microenvironment |
| WO2025016333A1 (zh) * | 2023-07-14 | 2025-01-23 | 广州百吉生物制药有限公司 | 一种工程化免疫细胞及其制备和应用 |
| WO2025255080A1 (en) * | 2024-06-04 | 2025-12-11 | The Children's Hospital Of Philadelphia | Hypoxia inducible high-fidelity circuit |
| WO2026016166A1 (zh) * | 2024-07-19 | 2026-01-22 | 上海鑫湾生物科技有限公司 | 一种响应缺氧环境的差异化基因表达调控系统及其应用 |
| CN119491023A (zh) * | 2024-12-03 | 2025-02-21 | 北京再生世纪生物科技有限公司 | 一种基因修饰增强脐带间充质干细胞旁分泌功能的方法及其应用 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9803351D0 (en) | 1998-02-17 | 1998-04-15 | Oxford Biomedica Ltd | Anti-viral vectors |
| JP2002526083A (ja) * | 1998-09-23 | 2002-08-20 | オックスフォード バイオメディカ（ユーケイ）リミテッド | ポリヌクレオチド構築物およびその使用 |
| GB0009760D0 (en) | 2000-04-19 | 2000-06-07 | Oxford Biomedica Ltd | Method |
| US9738907B2 (en) * | 2002-02-01 | 2017-08-22 | Oxford Biomedica (Uk) Limited | Viral vector |
| US7446190B2 (en) | 2002-05-28 | 2008-11-04 | Sloan-Kettering Institute For Cancer Research | Nucleic acids encoding chimeric T cell receptors |
| GB0816096D0 (en) | 2008-09-04 | 2008-10-15 | Medigene Ltd | Diabetes t cell receptors |
| GB0908613D0 (en) | 2009-05-20 | 2009-06-24 | Immunocore Ltd | T Cell Reseptors |
| GB0911566D0 (en) | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| BR112013003647A2 (pt) | 2010-07-28 | 2017-11-07 | Immunocore Ltd | receptores de células t. |
| KR101232123B1 (ko) * | 2010-10-08 | 2013-02-12 | 연세대학교 산학협력단 | 재조합된 유전자발현 조절서열을 가지는 종양 특이적 발현이 개선된 유전자 전달체 |
| MX2014001222A (es) | 2011-07-29 | 2014-09-15 | Univ Pennsylvania | Receptores coestimuladores de cambio. |
| WO2013041865A1 (en) | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
| AU2013266968B2 (en) | 2012-05-25 | 2017-06-29 | Emmanuelle CHARPENTIER | Methods and compositions for RNA-directed target DNA modification and for RNA-directed modulation of transcription |
| MX370148B (es) | 2012-10-02 | 2019-12-03 | Memorial Sloan Kettering Cancer Center | Composiciones y su uso para inmunoterapia. |
| PL3360964T3 (pl) | 2012-12-06 | 2020-03-31 | Sigma-Aldrich Co. Llc | Modyfikacja i regulacja genomu oparta na crispr |
| CN113355357B (zh) | 2012-12-12 | 2024-12-03 | 布罗德研究所有限公司 | 对用于序列操纵的改进的系统、方法和酶组合物进行的工程化和优化 |
| ES2671004T3 (es) * | 2013-03-07 | 2018-06-04 | Baylor College Of Medicine | Dirección a CD138 en cáncer |
| WO2015092024A2 (en) * | 2013-12-20 | 2015-06-25 | Cellectis | Method of engineering multi-input signal sensitive t cell for immunotherapy |
| WO2016146819A1 (en) * | 2015-03-18 | 2016-09-22 | Apceth Gmbh & Co. Kg | Hypoxia-induced expression of therapeutic proteins in mesenchymal stem cells |
| GB201513540D0 (en) | 2015-07-31 | 2015-09-16 | King S College London | Therapeutic agents |
| GB201522592D0 (en) | 2015-12-22 | 2016-02-03 | Immunocore Ltd | T cell receptors |
| GB201604953D0 (en) | 2016-03-23 | 2016-05-04 | Immunocore Ltd | T cell receptors |
| GB201709866D0 (en) | 2017-06-20 | 2017-08-02 | Immunocore Ltd | T cell receptors |
| CN109280086B (zh) * | 2018-09-10 | 2021-03-16 | 上海市公共卫生临床中心 | 一种肿瘤微环境特异性活化的缺氧诱导型嵌合抗原受体 |
-
2019
- 2019-02-19 GB GBGB1902277.1A patent/GB201902277D0/en not_active Ceased
-
2020
- 2020-02-19 EP EP20708568.9A patent/EP3927734A1/en active Pending
- 2020-02-19 KR KR1020217030111A patent/KR20210132105A/ko not_active Withdrawn
- 2020-02-19 JP JP2021548250A patent/JP7684692B2/ja active Active
- 2020-02-19 BR BR112021016435A patent/BR112021016435A2/pt not_active Application Discontinuation
- 2020-02-19 US US17/431,859 patent/US20220195009A1/en active Pending
- 2020-02-19 AU AU2020224373A patent/AU2020224373B2/en active Active
- 2020-02-19 CA CA3130688A patent/CA3130688A1/en active Pending
- 2020-02-19 WO PCT/GB2020/050401 patent/WO2020169974A1/en not_active Ceased
- 2020-02-19 CN CN202080029850.8A patent/CN113710695A/zh active Pending
-
2021
- 2021-08-12 IL IL285587A patent/IL285587A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL285587A (en) | 2021-09-30 |
| KR20210132105A (ko) | 2021-11-03 |
| AU2020224373A1 (en) | 2021-08-26 |
| EP3927734A1 (en) | 2021-12-29 |
| WO2020169974A1 (en) | 2020-08-27 |
| GB201902277D0 (en) | 2019-04-03 |
| JP2022520285A (ja) | 2022-03-29 |
| JP7684692B2 (ja) | 2025-05-28 |
| CA3130688A1 (en) | 2020-08-27 |
| CN113710695A (zh) | 2021-11-26 |
| US20220195009A1 (en) | 2022-06-23 |
| AU2020224373B2 (en) | 2025-06-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021016435A2 (pt) | Receptores de antígenos quiméricos responsivos à hipóxia | |
| BR112021019411A2 (pt) | Métodos para a produção de células car-nk e uso das mesmas | |
| BR112021022666A2 (pt) | Frações de separação e seus métodos e uso | |
| CO2019007868A2 (es) | Anticuerpos agonistas anti-icos y sus usos | |
| MX2021001837A (es) | Constructos del receptor de celulas t y usos de los mismos. | |
| MX2025007532A (es) | Receptores de antigenos quimericos para el tratamiento del cancer | |
| CO2021012587A2 (es) | Receptores de células t mage a4 | |
| MX2020003504A (es) | Receptores de celulas t que reconocen p53 mutado. | |
| BR112018067679A2 (pt) | células que expressam múltiplas moléculas do receptor de antígeno quimérico (car) e seu uso | |
| EA202091566A1 (ru) | Содержащая нуклеиновую кислоту липидная наночастица и ее применение | |
| BR112021016272A2 (pt) | Receptores de antígeno quimérico anti-dll3 humanizados e usos dos mesmos | |
| EA201792420A1 (ru) | Композиции и способы перепрограммирования tcr с помощью гибридных белков | |
| BR112019007100A2 (pt) | composições e métodos para reprogramação de receptores de célula t com o uso de proteínas de fusão | |
| BR112019011065A2 (pt) | métodos para determinação da dosagem de células t car | |
| AR103726A1 (es) | Cristales de anticuerpos monoclonales anti-pd-1 humanos | |
| BR112017003505A2 (pt) | anticorpos e receptores de antígeno quiméricos específicos para cd19 | |
| MX390943B (es) | Receptores de antígeno quimérico cd33 y usos de los mismos. | |
| BR112022008514A2 (pt) | Terapia de células t com receptor de antígeno quimérico | |
| BR112017022845A2 (pt) | neoepítopos de câncer | |
| MX2019003298A (es) | Proteinas de union recombinantes y sus usos. | |
| BR112018070073A2 (pt) | receptores de antígeno quimérico e célula t e métodos de uso | |
| BR112019012570A8 (pt) | Anticorpos que se ligam especificamente à il-15 humana e seus usos, composição, método in vitro para detecção de il-15 ou um complexo de il-15 e receptor de il-15-alfa, polinucleotídeo, vetor e método de produção do dito anticorpo | |
| MX2020009371A (es) | Composiciones y métodos para la reprogramación de tcr mediante el uso de proteínas de fusión. | |
| CO2017000507A2 (es) | Receptor quimérico de antígeno bcma | |
| PE20181092A1 (es) | Anticuerpos anti-pd1 y metodos de uso |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette] |